2661 — QingSong Health Income Statement
0.000.00%
Last trade - 00:00- HK$39.29bn
- HK$40.76bn
- CNY945.01m
Annual income statement for QingSong Health, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 394 | 490 | 945 |
| Cost of Revenue | |||
| Gross Profit | 325 | 391 | 362 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 387 | 385 | 938 |
| Operating Profit | 6.34 | 105 | 7.38 |
| Net Income Before Taxes | 6.34 | 105 | 7.38 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -9.1 | 97.2 | 8.99 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Extraordinary Items | |||
| Net Income | -2.06 | 73.6 | 10.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -2.06 | 73.6 | 10.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.049 | 0.45 | 0.08 |